Julian Schardt
Papers
1
Total Citations
32
H-Index
1
About
Julian Schardt is a leading clinical researcher in urothelial carcinoma, with a primary focus on perioperative chemoimmunotherapy for muscle-invasive bladder cancer. His major contribution is pioneering the integration of immune checkpoint inhibitors with standard cisplatin-based chemotherapy in the neoadjuvant setting. As the lead author of the SAKK 06/17 phase II trial, Schardt demonstrated that combining durvalumab with cisplatin/gemcitabine is safe and shows promising efficacy, with a pathological complete response rate of 38% in the preplanned interim analysis. This work, cited 32 times, addresses the critical need to improve outcomes for patients with muscle-invasive urothelial carcinoma, where relapse rates remain high despite standard neoadjuvant chemotherapy. Schardt’s research sits at the intersection of immunotherapy and surgical oncology, helping to define a new treatment paradigm that may reduce recurrence and improve survival. His contributions are particularly notable for their translational impact, directly informing ongoing phase III trials and clinical practice guidelines. For students and researchers, Schardt’s work exemplifies how early-phase trials can generate the evidence needed to reshape standard of care in aggressive genitourinary malignancies.
Research Focus
Key Achievements
Top Papers
- 1